188 related articles for article (PubMed ID: 30540687)
1. Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry.
Vicent L; Esteban-Fernández A; Gómez-Bueno M; De-Juan J; Díez-Villanueva P; Iniesta ÁM; Ayesta A; González-Saldívar H; Rojas-González A; Bover-Freire R; Iglesias D; García-Aguado M; Perea-Egido JA; Martínez-Sellés M
J Cardiovasc Pharmacol; 2019 Feb; 73(2):118-124. PubMed ID: 30540687
[TBL] [Abstract][Full Text] [Related]
2. "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
Simpson J; Benson L; Jhund PS; Dahlström U; McMurray JJV; Lund LH
Cardiovasc Drugs Ther; 2019 Jun; 33(3):315-322. PubMed ID: 30903545
[TBL] [Abstract][Full Text] [Related]
3. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
Fudim M; Sayeed S; Xu H; Matsouaka RA; Heidenreich PA; Velazquez EJ; Yancy CW; Fonarow GC; Hernandez AF; DeVore AD
Circ Heart Fail; 2020 Apr; 13(4):e006645. PubMed ID: 32248695
[TBL] [Abstract][Full Text] [Related]
4. Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF Trial.
Vicent L; Esteban-Fernández A; Gómez-Bueno M; De-Juan J; Díez-Villanueva P; Iniesta ÁM; Ayesta A; González-Saldívar H; Rojas-González A; Bover-Freire R; Iglesias D; García-Aguado M; Perea-Egido JA; Martínez-Sellés M
J Cardiovasc Pharmacol; 2018 Aug; 72(2):112-116. PubMed ID: 29878937
[TBL] [Abstract][Full Text] [Related]
5. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.
DeVore AD; Mi X; Thomas L; Sharma PP; Albert NM; Butler J; Hernandez AF; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Fonarow GC
J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29895587
[TBL] [Abstract][Full Text] [Related]
7. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
[TBL] [Abstract][Full Text] [Related]
9. Effects of sacubutril/valsartan on nutritional status in heart failure with reduced ejection fraction.
Dereli S; Bayramoğlu A; Kaya A
J Cardiovasc Med (Hagerstown); 2020 Jan; 21(1):13-20. PubMed ID: 31714330
[TBL] [Abstract][Full Text] [Related]
10. Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.
Moliner-Abós C; Rivas-Lasarte M; Pamies Besora J; Fluvià-Brugues P; Solé-González E; Mirabet S; López López L; Brossa V; Pirla MJ; Mesado N; Álvarez-García J; Roig E
Cardiovasc Drugs Ther; 2019 Jun; 33(3):307-314. PubMed ID: 30820802
[TBL] [Abstract][Full Text] [Related]
11. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
[TBL] [Abstract][Full Text] [Related]
12. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
[TBL] [Abstract][Full Text] [Related]
13. Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction.
Okutucu S; Sabanoglu C; Yetis Sayin B; Aksoy H; Bursa N; Oto A
Acta Cardiol; 2020 Feb; 75(1):20-25. PubMed ID: 30513267
[No Abstract] [Full Text] [Related]
14. Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.
Pericas P; Mas-Lladó C; Ramis-Barceló MF; Valadrón I; Noris Mora M; Pasamar Márquez L; González Colino R; Forteza Albertí JF; Peral Disdier V; Rossello X
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):167-175. PubMed ID: 33599965
[TBL] [Abstract][Full Text] [Related]
15. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
[TBL] [Abstract][Full Text] [Related]
16. PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction.
Docherty KF; McMurray JJV
Cardiovasc Res; 2019 Nov; 115(13):e136-e139. PubMed ID: 31497841
[No Abstract] [Full Text] [Related]
17. Sacubitril/valsartan improves medium-term reverse left ventricular remodeling: why wait?
Santangelo G; Bursi F; Toriello F; Valli F; Tombolini E; Torta D; Bosotti L; Massironi L; Carugo S
J Cardiovasc Med (Hagerstown); 2019 Oct; 20(10):727-729. PubMed ID: 31169634
[No Abstract] [Full Text] [Related]
18. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ
Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756
[TBL] [Abstract][Full Text] [Related]
20. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
